Influence of histocompatibility genes on the clinical course of patients with relapsing-remitting multiple sclerosis treated with interferon beta-1a

被引：0
|
作者：
Fletcher, S.
Klein, T.
Pollak, L.
机构：
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S200 / S201
页数：2
相关论文
共 50 条
  • [31] Effect of different dosages of interferon beta-1a in relapsing-remitting MS patients
    Cocco, E
    Marchi, R
    Floris, G
    Mascia, MG
    Lai, M
    Deriu, M
    Sirco, A
    Mamusa, E
    Frau, J
    Marrosu, MG
    MULTIPLE SCLEROSIS, 2005, 11 : S77 - S77
  • [32] Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b
    Baum, K.
    O'Leary, C.
    Ferrer, F. Coret
    Klimova, E.
    Prochazkova, L.
    Bugge, J.
    MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (09) : 1153 - 1160
  • [33] Clinical characteristics of nonresponders to interferon beta therapy for relapsing-remitting multiple sclerosis
    Waubant, E
    Vukusic, S
    Confavreux, C
    NEUROLOGY, 2002, 58 (07) : A189 - A190
  • [34] Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis
    Fisher, E.
    Nakamura, K.
    Lee, J-C
    You, X.
    Sperling, B.
    Rudick, R. A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (05) : 668 - 676
  • [35] Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
    Sorensen, PS
    Ross, C
    Clemmesen, KM
    Bendtzen, K
    Frederiksen, JL
    Jensen, K
    Kristensen, O
    Petersen, T
    Rasmussen, S
    Ravnborg, M
    Stenager, E
    Koch-Henriksen, N
    LANCET, 2003, 362 (9391): : 1184 - 1191
  • [36] Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis
    Liu, Ying
    Vollmer, Timothy
    Havrdova, Eva
    Riester, Katherine
    Lee, Andrew
    Phillips, Glenn
    Wang, Ping
    Sabatella, Guido
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 11 : 18 - 24
  • [37] Assessment of driving performance in patients with relapsing-remitting multiple sclerosis during 24-month therapy with interferon beta-1a
    Stueckle, KF
    Sindern, E
    Kotterba, S
    MULTIPLE SCLEROSIS, 2005, 11 : S78 - S79
  • [38] Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis
    Patti, F.
    Amato, M. P.
    Bastianello, S.
    Caniatti, L.
    Di Monte, E.
    Ferrazza, P.
    Goretti, B.
    Gallo, P.
    Morra, V. Brescia
    Lo Fermo, S.
    Picconi, O.
    Tola, M. R.
    Trojano, M.
    MULTIPLE SCLEROSIS, 2010, 16 (01): : 68 - 77
  • [39] Effects of two different doses of subcutaneous interferon beta-1a treatment on cognition in patients with early relapsing-remitting multiple sclerosis
    Patti, F.
    Amato, M. P.
    Caniatti, L.
    Di Monte, E.
    Ferrazza, P.
    Goretti, B.
    Lo Fermo, S.
    Picconi, O.
    Tola, M. R.
    Trojano, M.
    MULTIPLE SCLEROSIS, 2007, 13 : S56 - S56
  • [40] Effect of Alemtuzumab vs. Interferon beta-1a on Brain Atrophy in Patients with Early, Active Relapsing-Remitting Multiple Sclerosis
    Zivadinov, Robert
    Dwyer, Michael
    Bergsland, Niels
    Hussein, Sara
    Durfee, Jackie
    Ramasamy, Deepa
    Cherneva, Mariya
    Willis, Laura
    Cox, Jennifer
    Kennedy, Cheryl
    Margolin, David
    Rizzo, Marco
    Palmer, Jeffrey
    NEUROLOGY, 2011, 76 (09) : A388 - A388
12345